SHAREHOLDER ALERT: Weiss Law Investigates Metacrine, Inc.
NEW YORK, Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Metacrine, Inc. ("Metacrine" or the "Company") (NASDAQ: MTCR), in connection with the acquisition of the Company by Equillium, Inc. ("Equillium") (NASDAQ: EQ). Under the terms of the merger agreement, Equillium will issue stock valued at a 25% premium over the net cash delivered at closing, which is estimated to be approximately $26 million.
If you own Metacrine shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
https://www.weisslaw.co/news-and-cases/mtcr
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]
Weiss Law is investigating whether (i) Metacrine's board of directors acted in the best interests of Company shareholders in agreeing to the merger, (ii) the merger consideration adequately compensates Metacrine's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.
Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]
SOURCE Weiss Law
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article